This led to the development of bevacizumab, an antibody blocking VEGF‐induced angiogenesis (Carmeliet & Jain, 2011) and thereby targeting the blood supply of malignant brain tumors (Jain et al, 2007). This evidence concerns the gene VEGFA and brain cancer.